Siponimod (BAF312) treatment leads to early MRI benefits in relapsing-remitting multiple sclerosis patients: Results from a phase 2 study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2012
This article has no abstract
Epistemonikos ID: 00dbf7c27049774865304816a05e1ee5c30f18f6
First added on: Apr 30, 2026